Lab
Linear Care Diagnostics
Linear Care Diagnostics was paid $1.37M by Medicaid between Feb 2022 and Dec 2024, across 66 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 30% of everything it billed.
33Billing provider infoLINEAR CARE DIAGNOSTICS
ADDISON, TX 75001
ADDISON, TX 75001
33aNPI1770157794assigned 05/14/2021
33bProvider typeClinical Medical Laboratory
28Total paid$1.37M
24GClaims106,437
24DCodes billed66
24AFirst – last monthFeb 2022 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#56 of 436
Median peer was paid$17K
This provider vs. median80×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 48,397 | $549K | |
| 2023 | 33,507 | $545K | |
| 2024incomplete | 24,533 | $280K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 30% | 13,911 | 6,933 | $413K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 14% | 4,502 | 1,337 | $191K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 10% | 7,951 | 4,023 | $142K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 8.6% | 4,133 | 2,334 | $118K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.8% | 6,416 | 1,552 | $94K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5.1% | 23,253 | 7,774 | $71K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 4.2% | 1,613 | 710 | $58K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 3.9% | 3,975 | 2,356 | $53K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.9% | 13,350 | 6,740 | $53K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.2% | 650 | 456 | $30K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.0% | 2,178 | 1,685 | $27K |
| 87481 | 1.4% | 567 | 449 | $19K |
54 more codes
| 87640 | 1.1% | 3,700 | $14K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.0% | 3,512 | $14K |
| 87581 | <1% | 1,439 | $12K | |
| 87486 | <1% | 1,438 | $12K | |
| 87529 | <1% | 566 | $8K | |
| 87631 | <1% | 698 | $6K | |
| 87500 | <1% | 1,889 | $4K | |
| 87511 | <1% | 566 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 566 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 566 | $4K |
| 87641 | <1% | 2,013 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 124 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 273 | $1K |
| 87653 | <1% | 236 | $1K | |
| 80074 | <1% | 73 | $1K | |
| 87563 | <1% | 132 | $859.95 | |
| 80061 | Lipid panel | <1% | 256 | $733.93 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 102 | $731.57 |
| 82607 | <1% | 222 | $689.42 | |
| 82746 | <1% | 215 | $662.42 | |
| 83880 | <1% | 55 | $613.81 | |
| 80050 | General health panel | <1% | 25 | $559.13 |
| 80053 | Comprehensive metabolic panel | <1% | 447 | $550.16 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 279 | $541.07 |
| 84153 | <1% | 124 | $529.55 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 335 | $514.14 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 362 | $447.01 |
| 84481 | <1% | 104 | $390.67 | |
| 86803 | <1% | 116 | $366.82 | |
| 86708 | <1% | 77 | $356.65 | |
| 86376 | <1% | 108 | $354.64 | |
| 86704 | <1% | 76 | $338.70 | |
| 83735 | <1% | 196 | $315.14 | |
| 86706 | <1% | 73 | $279.91 | |
| 84403 | <1% | 24 | $274.68 | |
| 83540 | <1% | 165 | $273.85 | |
| 83090 | <1% | 54 | $262.25 | |
| 81001 | <1% | 966 | $247.50 | |
| 86140 | <1% | 176 | $241.91 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 412 | $240.80 |
| 86703 | <1% | 55 | $222.57 | |
| 84439 | <1% | 118 | $214.04 | |
| 87340 | <1% | 28 | $133.01 | |
| 83970 | <1% | 28 | $108.18 | |
| 85652 | <1% | 117 | $95.61 | |
| 86709 | <1% | 21 | $91.12 | |
| 86317 | <1% | 12 | $70.92 | |
| 84100 | <1% | 31 | $70.64 | |
| 84134 | <1% | 20 | $38.28 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 341 | $28.05 |
| 83550 | <1% | 24 | $26.74 | |
| 86592 | <1% | 18 | $18.60 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 352 | $6.43 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, MATTHEW (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Osteophysiology LLC | Missoula, MT | $49K |
| Back to Health Chiropractic, PA | Bloomington, MN | $36K |
| Blue Hills Physical Therapy Center, LLC | Cameron, WI | $19K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.